Toll Free: 1-888-928-9744
Published: Dec, 2014 | Pages:
38 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Zeria Pharmaceutical Co Ltd - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Zeria Pharmaceutical Co Ltd - Product Pipeline Review - 2014', provides an overview of the Zeria Pharmaceutical Co Ltd's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Zeria Pharmaceutical Co Ltd's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Zeria Pharmaceutical Co Ltd including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Zeria Pharmaceutical Co Ltd's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Zeria Pharmaceutical Co Ltd's pipeline products Reasons to buy - Evaluate Zeria Pharmaceutical Co Ltd's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Zeria Pharmaceutical Co Ltd in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Zeria Pharmaceutical Co Ltd's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Zeria Pharmaceutical Co Ltd and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Zeria Pharmaceutical Co Ltd - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Zeria Pharmaceutical Co Ltd and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Zeria Pharmaceutical Co Ltd Snapshot 5 Zeria Pharmaceutical Co Ltd Overview 5 Key Information 5 Key Facts 5 Zeria Pharmaceutical Co Ltd - Research and Development Overview 6 Key Therapeutic Areas 6 Zeria Pharmaceutical Co Ltd - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Pipeline Products - Partnered Products 10 Partnered Products/Combination Treatment Modalities 11 Pipeline Products - Out-Licensed Products 12 Out-Licensed Products/Combination Treatment Modalities 13 Zeria Pharmaceutical Co Ltd - Pipeline Products Glance 14 Zeria Pharmaceutical Co Ltd - Late Stage Pipeline Products 14 Phase III Products/Combination Treatment Modalities 14 Zeria Pharmaceutical Co Ltd - Clinical Stage Pipeline Products 15 Phase II Products/Combination Treatment Modalities 15 Phase I Products/Combination Treatment Modalities 16 Zeria Pharmaceutical Co Ltd - Drug Profiles 17 acotiamide hydrochloride 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 mycobacterium tuberculosis ext 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 polaprezinc 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 ZOSA-0 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 ZOY-60 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Z-360 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 E-3710 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 ferric carboxymaltose 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 Zeria Pharmaceutical Co Ltd - Pipeline Analysis 26 Zeria Pharmaceutical Co Ltd - Pipeline Products by Target 26 Zeria Pharmaceutical Co Ltd - Pipeline Products by Route of Administration 27 Zeria Pharmaceutical Co Ltd - Pipeline Products by Molecule Type 28 Zeria Pharmaceutical Co Ltd - Pipeline Products by Mechanism of Action 29 Zeria Pharmaceutical Co Ltd - Recent Pipeline Updates 30 Zeria Pharmaceutical Co Ltd - Dormant Projects 32 Zeria Pharmaceutical Co Ltd - Discontinued Pipeline Products 33 Discontinued Pipeline Product Profiles 33 acotiamide hydrochloride 33 Zeria Pharmaceutical Co Ltd - Locations And Subsidiaries 34 Head Office 34 Other Locations & Subsidiaries 34 Appendix 37 Methodology 37 Coverage 37 Secondary Research 37 Primary Research 37 Expert Panel Validation 37 Contact Us 38 Disclaimer 38
List of Tables Zeria Pharmaceutical Co Ltd, Key Information 5 Zeria Pharmaceutical Co Ltd, Key Facts 5 Zeria Pharmaceutical Co Ltd - Pipeline by Indication, 2014 7 Zeria Pharmaceutical Co Ltd - Pipeline by Stage of Development, 2014 8 Zeria Pharmaceutical Co Ltd - Monotherapy Products in Pipeline, 2014 9 Zeria Pharmaceutical Co Ltd - Partnered Products in Pipeline, 2014 10 Zeria Pharmaceutical Co Ltd - Partnered Products/ Combination Treatment Modalities, 2014 11 Zeria Pharmaceutical Co Ltd - Out-Licensed Products in Pipeline, 2014 12 Zeria Pharmaceutical Co Ltd - Out-Licensed Products/ Combination Treatment Modalities, 2014 13 Zeria Pharmaceutical Co Ltd - Phase III, 2014 14 Zeria Pharmaceutical Co Ltd - Phase II, 2014 15 Zeria Pharmaceutical Co Ltd - Phase I, 2014 16 Zeria Pharmaceutical Co Ltd - Pipeline by Target, 2014 26 Zeria Pharmaceutical Co Ltd - Pipeline by Route of Administration, 2014 27 Zeria Pharmaceutical Co Ltd - Pipeline by Molecule Type, 2014 28 Zeria Pharmaceutical Co Ltd - Pipeline Products by Mechanism of Action, 2014 29 Zeria Pharmaceutical Co Ltd - Recent Pipeline Updates, 2014 30 Zeria Pharmaceutical Co Ltd - Dormant Developmental Projects,2014 32 Zeria Pharmaceutical Co Ltd - Discontinued Pipeline Products, 2014 33 Zeria Pharmaceutical Co Ltd, Other Locations 34 Zeria Pharmaceutical Co Ltd, Subsidiaries 35
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.